Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

BACKGROUND: Predictive biomarker development is a key challenge for novel cancer therapeutics. We explored the feasibility of next-generation sequencing (NGS) to validate exploratory genomic biomarkers that impact phase I trial selection. METHODS: We prospectively enrolled 158 patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150267/
https://www.ncbi.nlm.nih.gov/pubmed/24983367
http://dx.doi.org/10.1038/bjc.2014.350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150267/
https://www.ncbi.nlm.nih.gov/pubmed/24983367
http://dx.doi.org/10.1038/bjc.2014.350

Ejemplares similares